NCT00667199View on ClinicalTrials.gov

BAY88-8223, Does Response Study in HRPC Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

May 30, 2005

Primary Completion Date

April 1, 2008

Study Completion Date

October 6, 2009

Conditions

Hormone Refractory Prostate CancerBone Metastases

Interventions

DRUG

Radium-223 dichloride (BAY88-8223)

The required volume of study drug to be administered to a patient was calculated using the patient's body weight, the dose (5 , 25 , 50 or 100 kBq/kg b.w.)